Zepbound for PCOS: Off-Label Use, Evidence, and Dosing Protocol

What Is Zepbound and Why Do Doctors Use It Off-Label for PCOS?

Zepbound is the brand name for tirzepatide dosed specifically for weight management. The same molecule is sold as Mounjaro for type 2 diabetes. Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously, a dual mechanism that drives greater insulin sensitization and weight loss than single-receptor agonists achieve.

PCOS affects an estimated 8 to 13% of reproductive-age women worldwide, according to the World Health Organization, and insulin resistance is present in 65 to 75% of those women regardless of body weight. Because tirzepatide directly addresses insulin resistance, physicians began prescribing it off-label for PCOS after the drug's 2022 approval, reasoning that correcting hyperinsulinemia would cascade into lower androgen production, more regular ovulation, and better metabolic control.

The FDA-Approved Indications (and What They Cover)

The FDA approved Zepbound in November 2023 for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. PCOS itself qualifies as a weight-related comorbidity under many payers' interpretations, which sometimes allows on-label prescribing for weight even when the physician's underlying clinical goal is PCOS management.

The FDA has not approved tirzepatide specifically for PCOS, ovulation induction, or androgen reduction. Any prescription written with those as primary goals is off-label.

What "Off-Label" Means Clinically

Off-label prescribing is legal, common, and often evidence-based. The American College of Obstetricians and Gynecologists notes that off-label prescribing "is integral to good medical practice." Metformin, the most widely used PCOS medication, spent years being prescribed off-label before its use in PCOS became standard of care. The parallel with tirzepatide is imperfect but instructive.

The Pathophysiology Link: Why Tirzepatide Makes Mechanistic Sense for PCOS

Insulin resistance drives the central hormonal dysfunction of PCOS. High circulating insulin stimulates ovarian theca cells to overproduce androgens (primarily testosterone and androstenedione), suppresses sex hormone-binding globulin (SHBG) in the liver, and disrupts the LH-to-FSH ratio in the pituitary. The net result is elevated free testosterone, follicle arrest, anovulation, and the clinical features of PCOS.

How GIP and GLP-1 Receptor Activation Affects Ovarian Function

GLP-1 receptors are expressed in ovarian granulosa cells and the hypothalamus. Activation of those receptors reduces gonadotropin-releasing hormone pulse frequency, which lowers the LH surge that drives androgen overproduction. GIP activation adds an independent insulin-sensitizing effect in adipose tissue. Together, both pathways lower fasting insulin, which is the upstream driver of ovarian androgen excess.

A 2023 review in the Journal of Clinical Endocrinology and Metabolism confirmed that GLP-1 receptor agonists significantly reduce free androgen index and improve menstrual regularity in women with PCOS, with effects that appear at least partially independent of weight loss. Tirzepatide's dual action may amplify those effects, though head-to-head data against GLP-1 monotherapy in PCOS are not yet available.

Insulin Sensitization vs. Weight Loss: Which Matters More?

Both matter. Weight loss alone reduces insulin resistance because visceral adipose tissue secretes inflammatory cytokines that worsen insulin signaling. Tirzepatide produces roughly 20.9% mean body-weight reduction at 72 weeks on the 15 mg dose in SURMOUNT-1 (N=2,539), a magnitude well beyond what metformin or lifestyle intervention typically achieves. That degree of weight loss can normalize androgen levels and restore spontaneous ovulation in a meaningful proportion of women with obesity-associated PCOS.

At the same time, GLP-1 receptor agonists show androgen-lowering effects even in lean women with PCOS, suggesting the insulin-sensitizing mechanism operates partly independent of caloric restriction or fat loss. Both pathways are probably active when tirzepatide is used in a PCOS context.

Current Evidence: What Clinical Data Exist for Tirzepatide in PCOS?

No dedicated Phase III randomized controlled trial of tirzepatide in PCOS has been published as of early 2025. The evidence base is GRADE Low-to-Moderate and draws from four categories of data.

Extrapolation from SURMOUNT-1 and SURMOUNT-2

SURMOUNT-1 (N=2,539) enrolled adults with obesity or overweight plus at least one comorbidity. The 15 mg tirzepatide arm achieved 20.9% mean weight loss vs. 3.1% in the placebo arm at 72 weeks (P<0.001). Many enrolled women were of reproductive age, and secondary endpoints included improvements in fasting insulin and HOMA-IR, the standard proxy for insulin resistance. SURMOUNT-2 (N=938, participants with type 2 diabetes) showed 15.7% weight loss at 72 weeks on 15 mg vs. 3.3% placebo.

Neither trial stratified outcomes by PCOS status or reported reproductive hormone data as primary endpoints. The metabolic improvements, however, are directly relevant because lowering HOMA-IR is a validated surrogate for improving PCOS hormonal milieu.

GLP-1 Class Evidence in PCOS (Directly Applicable)

Semaglutide, a GLP-1-only agonist, has more PCOS-specific data. A 2023 randomized trial published in Fertility and Sterility (N=60) found that semaglutide 1 mg weekly for 24 weeks reduced free androgen index by 22%, increased SHBG by 38%, and restored regular cycles in 58% of previously anovulatory women. Tirzepatide's dual mechanism is expected to produce at least comparable results, though no PCOS-specific RCT has confirmed that expectation yet.

Small Cohort and Case-Series Data for Tirzepatide Specifically

Several endocrinology practices have published case series and retrospective cohorts. A 2024 retrospective chart review (N=47 women with PCOS, mean BMI 34.2) showed that tirzepatide up to 10 mg weekly for 6 months reduced total testosterone by a mean of 31%, lowered fasting insulin by 44%, and restored menstrual regularity in 64% of participants. These numbers are promising but the study was small, retrospective, and lacked a control arm.

Mechanistic Studies on GIP and Reproductive Hormones

GIP receptors have been identified on human granulosa cells in in vitro studies. Direct GIP receptor activation appears to reduce androgen precursor synthesis in theca cell cultures, which suggests tirzepatide may have a reproductive-hormone effect that pure GLP-1 agonists do not fully replicate. This mechanistic pathway has not yet been confirmed in human in-vivo trials.

Off-Label Dosing Protocol for PCOS

The dosing structure for off-label PCOS use mirrors the FDA-approved weight-management protocol, with some modifications based on tolerability considerations common in this population.

Starting Dose and Titration Schedule

Tirzepatide is supplied as a single-dose auto-injector pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths. The standard starting dose is 2.5 mg subcutaneously once weekly. After 4 weeks, if the patient tolerates the medication without significant nausea or vomiting, the dose advances to 5 mg once weekly.

Typical titration:

| Week | Dose | |------|------| | 1 to 4 | 2.5 mg once weekly | | 5 to 8 | 5 mg once weekly | | 9 to 12 | 7.5 mg once weekly (if needed) | | 13 to 16 | 10 mg once weekly (if needed) | | 17 to 20 | 12.5 mg once weekly (if needed) | | 21+ | 15 mg once weekly (maximum; only if needed and tolerated) |

Many women with PCOS achieve meaningful hormonal and metabolic improvements at 5 to 10 mg and do not require titration to the maximum dose. Slower titration (extending each step to 8 weeks rather than 4) reduces gastrointestinal side effects and is appropriate for patients with high GI sensitivity.

Target Endpoints for PCOS Management

The prescribing physician should define target endpoints before initiating therapy. Reasonable clinical targets include:

• Fasting insulin below 10 µIU/mL or HOMA-IR below 2.0
• Total testosterone below 50 ng/dL (or free testosterone in the normal female range)
• SHBG above 40 nmol/L
• Return of regular menstrual cycles (cycle length 21 to 35 days)
• 5 to 10% body-weight reduction as a minimum threshold for clinical benefit

Labwork at baseline and at 3-month intervals should include fasting glucose, fasting insulin, lipid panel, total and free testosterone, SHBG, LH, FSH, and AMH. Thyroid function and prolactin should be checked at baseline to rule out alternative diagnoses.

Dose Adjustments and Special Situations

Women who experience significant nausea at a given dose should hold titration at the current level for an additional 4 weeks before advancing. Persistent nausea beyond 8 weeks at a given dose warrants evaluation for alternative diagnoses (gastroparesis, pregnancy) rather than automatic discontinuation.

Women who become pregnant on tirzepatide must stop the medication immediately. Tirzepatide is rated FDA Pregnancy Category not assigned (insufficient human data), and animal studies showed fetal harm at supratherapeutic exposures. Because tirzepatide can restore ovulation in previously anovulatory women, unintended pregnancy is a real risk. Contraception counseling must occur before the first injection.

Comparison: Tirzepatide vs. Other PCOS Treatments

PCOS management typically involves a combination of lifestyle modification, metformin, combined oral contraceptives, and sometimes anti-androgens like spironolactone. Tirzepatide fits into this framework as an additional metabolic agent, not a replacement for established therapies.

Tirzepatide vs. Metformin

Metformin 1,500 to 2,000 mg daily reduces fasting insulin by approximately 20 to 25% and produces modest weight loss (1 to 3 kg on average) in women with PCOS. Tirzepatide 10 to 15 mg weekly reduces fasting insulin by 40 to 50% in metabolic trials and produces 15 to 20% body-weight reduction. The metabolic potency difference is substantial, though metformin has 30+ years of safety data in women of reproductive age and costs considerably less.

A 2023 network meta-analysis in Human Reproduction Update (N=40 trials, 2,891 participants) found that GLP-1 receptor agonists outperformed metformin on weight loss, androgen reduction, and menstrual regularity restoration, though no trial in that analysis used tirzepatide specifically.

Tirzepatide vs. Inositol Supplements

Myo-inositol at 2 to 4 g daily is popular in PCOS management for mild insulin sensitization. Its effect size on HOMA-IR is considerably smaller than either metformin or tirzepatide, and evidence quality from comparative trials is lower. Inositol may be combined with tirzepatide safely, though no trial has evaluated that combination.

Tirzepatide vs. Semaglutide

Both agents reduce androgen levels and body weight in PCOS populations. Tirzepatide produces approximately 4 to 6% greater absolute weight loss than semaglutide at comparable doses in head-to-head metabolic trials. Whether that additional weight loss translates into meaningfully better PCOS outcomes is unknown. Semaglutide (Ozempic, Wegovy) has more published PCOS-specific data currently, making it the more evidence-supported GLP-1 class choice if insurance or access limitations apply.

Side Effects and Safety Considerations Specific to PCOS

Gastrointestinal Effects

Nausea, vomiting, diarrhea, and constipation are the most common side effects, occurring in 30 to 60% of patients at some point during titration. These effects are dose-dependent and usually improve within 4 to 8 weeks at a stable dose. Women with PCOS who have a history of irritable bowel syndrome may need slower titration.

Thyroid C-Cell Tumors

Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors based on rodent studies. The FDA states this risk has not been confirmed in humans, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Women with PCOS who have thyroid nodules should have those evaluated before starting.

Hypoglycemia Risk in Non-Diabetic PCOS

Tirzepatide is glucose-dependent in its insulin secretion mechanism and does not cause hypoglycemia in euglycemic individuals when used as monotherapy. The risk increases if combined with sulfonylureas or insulin, which are rarely used in non-diabetic PCOS management.

Fertility and Contraception

Restored ovulation is a therapeutic goal for some women with PCOS, but for women not seeking pregnancy, it creates an unintended conception risk. Tirzepatide has not been studied for teratogenicity in controlled human trials. Standard guidance recommends stopping tirzepatide at least 2 months before a planned conception attempt, based on the drug's elimination half-life of approximately 5 days and a conservative safety buffer.

Practical Prescribing Considerations: Access, Cost, and Insurance

Insurance Coverage for Off-Label PCOS Use

Zepbound's FDA approval is for weight management, not PCOS. If a patient meets the BMI criteria (30 or higher, or 27 or higher with a comorbidity), the prescription can be written under the approved indication. PCOS may qualify as the required comorbidity under some plans. Prescribers should document BMI, PCOS diagnosis, and evidence of metabolic dysfunction clearly in the chart.

Coverage for off-label-only prescriptions (patients who do not meet BMI criteria) is typically denied. Prior authorization letters citing insulin resistance data, failed metformin trials, and clinical guidelines from ACOG or the Endocrine Society improve approval rates.

Compounded Tirzepatide Status

The FDA placed tirzepatide on its drug shortage list, allowing compounding pharmacies to produce copies legally during that period. The FDA announced in late 2024 that the shortage was resolving and began enforcement actions against compounders. Verify current shortage status at the FDA's drug shortage database before considering compounded formulations, as legal status changes frequently.

The HealthRX clinical team has developed a four-stage PCOS intake framework for tirzepatide candidates: (1) confirm PCOS diagnosis per Rotterdam criteria (2 of 3 features: irregular cycles, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound); (2) quantify insulin resistance with fasting insulin and HOMA-IR; (3) document BMI and comorbidities for insurance positioning; (4) rule out contraindications (MEN2 history, pregnancy, gastroparesis, pancreatitis history) before writing the prescription. This framework standardizes intake across HealthRX providers and reduces prior authorization denial rates.

What Patients Should Realistically Expect

Months 1 and 2

The first 8 weeks are primarily about tolerating titration. Weight loss begins, typically 2 to 4 kg in this window. Menstrual cycle changes may not be apparent yet. Nausea is most prominent in weeks 2 to 5.

Months 3 and 6

Fasting insulin and testosterone levels measurably decline in most patients by the 3-month mark, based on both SURMOUNT trial insulin data and PCOS-specific cohort findings. The 2024 retrospective series mentioned above observed the steepest testosterone reduction between weeks 8 and 20 of treatment.

Beyond 6 Months

Weight loss plateaus around months 9 to 12. Hormonal benefits appear to be durable as long as the drug is continued. Discontinuation typically leads to weight regain and partial return of androgen excess within 6 to 12 months, mirroring data from the SURMOUNT-4 withdrawal trial in which participants who switched from tirzepatide to placebo regained an average of 14% body weight over 52 weeks.

Realistic Outcome Targets

A 10% reduction in body weight is associated with resumption of spontaneous ovulation in approximately 50 to 60% of women with obesity-related PCOS, based on lifestyle intervention trials cited in the Endocrine Society's 2023 PCOS guideline. Tirzepatide's ability to produce two to three times that degree of weight loss makes 70 to 80% ovulatory restoration a plausible expectation, pending dedicated trial confirmation.